Phase Separation of Signaling Molecules Promotes T Cell Receptor Signal Transduction
Scientists biochemically reconstituted a 12-component signaling pathway on model membranes, beginning with T cell receptor (TCR) activation and ending with actin assembly. When TCR phosphorylation was triggered, downstream signaling proteins spontaneously separated into liquid-like clusters that promoted signaling outputs both in vitro and in human Jurkat T cells. [Science] Abstract
Emerging Insights into Natural Killer Cells in Human Peripheral Tissues
Scientists provide a comprehensive overview of the emerging knowledge about the development, differentiation and function of human natural killer (NK) cell populations, with a particular focus on NK cells in peripheral tissues. [Nat Rev Immunol] Abstract
Visit our reviews page to see a complete list of reviews in the human immunology research field.
SCIENCE NEWS
Genentech Highlights Personalized Medicines and Cancer Immunotherapies
Genentech announced new results from 19 approved and investigational medicines will be presented. More than 200 abstracts have been accepted across eight cancer types, including four “late breakers” and nearly 30 oral presentations. [Press release from Genentech, Inc. discussing research to be presented at the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting, Chicago] Press Release
Government of Canada Combats Chronic Health Conditions
The Honorable Jane Philpott, Minister of Health, announced an investment of $16 million over five years to support new research that will help find new ways to prevent or treat chronic conditions affecting millions of Canadians. [Government of Canada] Press Release
Agenus Commences Phase I Clinical Trial of Its CTLA-4 Checkpoint Antibody to Treat Solid Tumors
Agenus Inc. announced that the first patient has been dosed in the company’s Phase I clinical trial of AGEN1884, an anti-CTLA-4 checkpoint antibody. The open-label, multicenter trial in patients with advanced or refractory cancer is designed to evaluate the safety of AGEN1884 and determine the estimated maximum tolerated dose. [Agenus Inc.] Press Release